Leerink Partnrs Decreases Earnings Estimates for Beigene

Beigene, Ltd. (NASDAQ:ONC - Free Report) - Research analysts at Leerink Partnrs decreased their FY2026 earnings per share estimates for Beigene in a report issued on Monday, April 28th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of $6.73 for the year, down from their previous forecast of $7.06. The consensus estimate for Beigene's current full-year earnings is ($5.82) per share.

Other equities research analysts also recently issued research reports about the company. Guggenheim reiterated a "buy" rating on shares of Beigene in a research report on Wednesday, April 16th. Macquarie increased their price target on Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. JPMorgan Chase & Co. lifted their price target on Beigene from $311.00 to $317.00 and gave the stock an "overweight" rating in a research note on Monday, April 21st. Bank of America raised shares of Beigene from a "neutral" rating to a "buy" rating and upped their price objective for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Finally, JMP Securities set a $348.00 target price on shares of Beigene in a research report on Friday, February 28th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $318.88.

Beigene Trading Up 0.1 %

ONC stock traded up $0.13 on Wednesday, hitting $255.77. 180,351 shares of the company's stock traded hands, compared to its average volume of 478,851. The firm has a market cap of $25.30 billion, a PE ratio of -31.04, a price-to-earnings-growth ratio of 7.73 and a beta of 0.49. Beigene has a 1-year low of $141.31 and a 1-year high of $287.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The stock's fifty day moving average is $248.16.

Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%.

Insider Activity

In related news, insider Xiaodong Wang sold 41,760 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $242.66, for a total value of $10,133,481.60. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bros. Advisors Lp Baker sold 732,827 shares of the company's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $260.00, for a total value of $190,535,020.00. Following the sale, the director now directly owns 730,642 shares of the company's stock, valued at $189,966,920. The trade was a 50.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,146,048 shares of company stock worth $295,198,300. 6.62% of the stock is owned by corporate insiders.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.